Onxeo Announces Evolution in the Board of Directors


  · Mr. Patrick Langlois is planning to step down from the chairmanship in early
2016 for personal reasons
  · Mr. Joseph Zakrzewski is joining the Board and is expected to be appointed
Non-Executive Chairman in 2016
PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE (http://www.businesswire.com/))--
Regulatory News:

Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris, NASDAQ Copenhagen:
ONXEO), an innovative biopharmaceutical company specializing in the development
of orphan oncology drugs, today announced that Mr. Joseph Zakrzewski is joining
the Board of Directors as a Permanent Attendee with the view of being appointed
Board Member and Non-Executive Chairman early 2016. Mr. Patrick Langlois,
currently Non-Executive Chairman of the Board, has announced that he will step
down from his chairmanship and board position for personal reasons and will pass
his responsibility to Mr. Zakrzewski after the board meeting scheduled for the
end of January 2016.

When Mr. Joseph Zakrzewski is appointed as chairman, Mrs. Danièle Guyot
-Caparros, board member and Chairman of the Audit Committee, will be appointed
Senior Independent Director in charge of good governance practices, especially
in the French environment.

Mr. Joseph Zakrzewski has more than 25 years of experience in the global
healthcare industry with a focus in the United States, where he has successfully
handled leadership positions in public and private companies as well as venture
capital. Throughout his career, he has developed an extensive range of
expertise, heading Global Corporate Business Development for Eli Lilly prior to
being appointed to executive positions at biotechnology companies (Reliant
Pharmaceuticals, Xcellerex, and Amarin) where he acquired a broad knowledge of
the US biotechnology environment, innovation management, and healthcare
-specialized financing. Mr. Zakrzewski currently holds board member positions
with a number of US and European healthcare companies.

“We are delighted to welcome Joe to Onxeo. His experience in corporate
development, his knowledge of the US healthcare environment and the financial
community are impressive and I am pleased to hand over my responsibilities to
him. We are convinced that Joe will bring a sound value to the Board of
Directors in supporting the management team as it continues to drive the company
forward. Over the coming months we are planning on a smooth transition in early
2016,” comments Patrick Langlois, Chairman of the Board of Onxeo. “I have been
privileged to witness and contribute to Onxeo’s new focus on high potential
orphan oncology products. I am very proud of what we have achieved, together
with the Board of Directors and the management team that I would like to thank
them both for their trust and commitment.”

Mr. Joseph Zakrzewski, Permanent Attendee and future Chairman of the Board of
Directors of Onxeo, added: “Onxeo is a very promising company with a clear
position in an attractive market, a large and well-advanced pipeline and a
strong management team. I am delighted to join Onxeo’s board, a group of highly
experienced professionals and I am impressed with the level of commitment and
professionalism shown within the company. I truly believe that this company has
everything it needs to build a great future and I am very excited to have the
opportunity to be part of this entrepreneurial adventure that I will support in
all possible ways.”

Biography:

Joseph Zakrzewski has more than 25 years of experience in the healthcare
industry. His career started with Eli Lilly & Company in the USA: He joined as
process engineer with responsibility for biologics development & manufacturing
(1988-1991), became Senior Financial Analyst (1991-1993) and Head of
Manufacturing and Development (1993-1995), then Manager and Director of
Corporate Business Development (1995-2003), before being appointed VP Global
Corporate Business Development (2003-2005). He was Chief Operating Officer of
Reliant Pharmaceuticals (2005-2007), and then joined the biotechnology company
Xcellerex as CEO (2007-2010). From 2010 to 2013, he was Chairman and CEO of
Amarin Corporation (Ireland), where he remains a director. He has also been a
venture partner at Orbimed Advisors, one of the leading VC funds dedicated to
the healthcare industry (2010-2011).

Joseph Zakrzewski is a board member with several biotechnology companies in
Europe and in the USA, public and private, including Insulet Corporation, Amarin
Corporation, Thrasos Therapeutics, Acceleron Pharma, Gliacure Inc., and SiteOne
Therapeutics.

A US citizen, Joseph Zakrzewski received a BS in Chemical Engineering and an MS
in Biochemical Engineering from Drexel University. He has an MBA in Finance from
the University of Indiana.

About Onxeo

Onxeo has the vision to become a global leader and pioneer in oncology, with a
focus on orphan or rare cancers, through developing innovative therapeutic
alternatives designed to “make the difference”. The Onxeo team is determined to
develop innovative medicines that provide patients with hope and significantly
improve their lives.

Key orphan oncology products at the advanced development stage are:
Livatag® (doxorubicin Transdrug™): Phase III in hepatocellular carcinoma
Validive® (clonidine Lauriad®): Phase II in severe oral mucositis: Positive
final results
Beleodaq® (belinostat): Registered in the US in 2nd-line treatment of peripheral
T-cell lymphoma

For more information, visit the
website www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3
A 
%2F%2Fwww.onxeo.com&esheet=51195952&newsitemid=0&lan=en
-US&anchor=www.onxeo.com&index=1&md5=200f32a965229c40008b3808dc5d07d7)

To receive our press releases and newsletters, please register
on: http://www.onxeo.com/en/newsletter/ (http://cts.businesswire.com/ct/CT?id=sm
a 
rtlink&url=http%3A%2F%2Fwww.onxeo.com%2Fen%2Fnewsletter%2F&esheet=51195952&newsi
t 
emid=0&lan=en
-US&anchor=http%3A%2F%2Fwww.onxeo.com%2Fen%2Fnewsletter%2F&index=2&md5=2697955bc
e 
fe709867eef523dcbaf4db)

Follow us on twitter @Onxeo_

Disclaimer

This communication expressly or implicitly contains certain forward-looking
statements concerning Onxeo and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors, which could cause the
actual results, financial condition, performance or achievements of Onxeo to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Onxeo is providing this
communication as of this date and does not undertake to update any forward
-looking statements contained herein as a result of new information, future
events or otherwise. For a discussion of risks and uncertainties which could
cause actual results, financial condition, performance or achievements of Onxeo
to differ from those contained in the forward-looking statements, please refer
to the Risk Factors ("Facteurs de Risque") section of the 2014 Reference
Document filed with the AMF on April 14, 2015, which is available on the AMF
website (http://www.amf
-france.org (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww
. 
amf-france.org&esheet=51195952&newsitemid=0&lan=en
-US&anchor=http%3A%2F%2Fwww.amf
-france.org&index=3&md5=5fa322d23303d13b9acdf8b66ec11981)) or on the company’s
website
(www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2F
w 
ww.onxeo.com&esheet=51195952&newsitemid=0&lan=en
-US&anchor=www.onxeo.com&index=4&md5=fa65269474c8c6d97746bdd353814b12)).
Onxeo
Judith Greciet, CEO
j.greciet@onxeo.com
Nicolas Fellmann, CFO
n.fellmann@onxeo.com
+33 1 45 58 76 00
or
Caroline Carmagnol and Florence Portejoie, +33 6 64 18 99 59 / +33 6 47 38 90 04
onxeo@alizerp.com

Attachments

10062642.pdf